Patient characteristics Intervention Comparison Length of followup

Similar documents
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Non ST Elevation-ACS. Michael W. Cammarata, MD

Journal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium

4. Which survey program does your facility use to get your program designated by the state?

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice

APPENDIX F: CASE REPORT FORM

Acute Coronary Syndrome. Sonny Achtchi, DO

The ESC Registry on Chronic Ischemic Coronary Disease

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

PROMUS Element Experience In AMC

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Supplement materials:

Management of cardiovascular disease - coronary interventions -

A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS

Supplementary Material to Mayer et al. A comparative cohort study on personalised

Characteristics of Transient ST-Elevation versus ST-Elevation and Non-ST-Elevation Myocardial Infarction

Controversies in Cardiac Pharmacology

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Timing of angiography for high- risk ACS

Early discharge in selected patients after an acute coronary syndrome can it be safe?

An update on the management of UA / NSTEMI. Michael H. Crawford, MD

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY

The Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium

DECLARATION OF CONFLICT OF INTEREST

Benoy N Shah 1,2,3, Gothandaraman Balaji 1, Abdalla Alhajiri 1, Ihab Ramzy 1, Shahram Ahmadvazir 1 & Roxy Senior 1,2,3

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD

Cardiogenic Shock. Carlos Cafri,, MD

Downloaded from:

Patient referral for elective coronary angiography: challenging the current strategy

Women and Vascular Disease

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial

The MAIN-COMPARE Study

Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES

DECLARATION OF CONFLICT OF INTEREST

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION

Disclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center

NSTE ACS. Timing of intervention

Statin pretreatment and presentation patterns in patients with acute coronary syndromes

Adults With Diagnosed Diabetes

Inter-regional differences and outcome in unstable angina

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Coronary Artery Disease: Revascularization (Teacher s Guide)

SUPPLEMENTAL MATERIAL

A Report From the Second National Registry of Myocardial Infarction (NRMI-2)

Managing Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics

Subsequent management and therapies

STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION. STREAM 1Y AHA 2013 P Sinnaeve

DUKECATHR Dataset Dictionary

Advances in Cardiovascular Diagnosis and Therapy. No disclosure or conflicts. Outline

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Dr Joan Leighton. Professor Gerry Devlin. 14:00-14:55 WS #106: Whats Topical in Cardiology 15:05-16:00 WS #116: Whats Topical in Cardiology (Repeated)

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

This event does not qualify for continuing medical education (CME), continuing nursing education (CNE), or continuing education (CE) credit

Acute Myocardial Infarction. Willis E. Godin D.O., FACC

TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS

Mean INTERHEART Risk Score (IHRS) Yusuf et al NEJM 2014

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial

Exercise treadmill testing is frequently used in clinical practice to

Rate Control versus Rhythm Control in NSTEMI

Lessons learned From The National PCI Registry

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

The MAIN-COMPARE Registry

Ischemic Heart Disease Interventional Treatment

Cindy L. Grines MD FACC FSCAI

Belinda Green, Cardiologist, SDHB, 2016

Supplementary Online Content

Approach to Multi Vessel disease with STEMI

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

David A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio

Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events

Journal of the American College of Cardiology Vol. 46, No. 8, by the American College of Cardiology Foundation ISSN /05/$30.

egfr > 50 (n = 13,916)

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

Preoperative Cardiac Risk Assessment: Approach & Guidelines

Perioperative Medical Therapy: Beta Blockers, Statins, ACE-Inhibitors, ARB Effects on Mortality

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI

Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary

Clinical Outcome in Patients with Aortic Stenosis

Treatment strategies and risk stratification in acute coronary syndromes Damman, P.

Management of Acute Myocardial Infarction

Transcription:

ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing in consecutive patients after non-stelevation myocardial infarction: results the acute syndromes registry. Eur J Cardiovasc Prev Rehabil. 2006; 13(3):457-463. Study type/ Evidence level Observational Registry study (Cohort) Level 2+ Number patients N (NSTEMI) = 5281 Patient characteristics Intervention Comparison Length followup Inclusion: ACOS Registry: Consecutive patients between 2000-2002 with acute syndrome presenting with NSTEMI. NSTEMI defined as persistent angina > 20 min; troponin T or I elevation; no ST-elevation (ECG could show ST-depression or T inversion, or could be normal) No exercise (N=4184) Exercise (N=1097) P value Mean age 69.0 64.6 <0.01 Women 35.3 28.4 <0.01 Prior MI 26.1 22.7 0.02 Prior stroke / TIA Peripheral vascular disease Diabetes Mellitus Renal Failure Systemic hypertension Ejection fraction <40% 9.3 4.8 <0.01 10.1 6.3 <0.01 32.4 25.1 <0.01 4.5 2.6 <0.01 71.0 68.2 0.07 22.9 12.0 <0.01 In hospital 72.4 77.3 <0.01 Predischarge exercise N=1097 (20%) (78.2% treadmill echocardiography, 7.5% stress echocardiography, 12.5% stress scintigraphy, 1.8% no info on type exercise ) Mean duration hospital stay: 10 days No pre discharge exercise N=4184 One year measures All cause mortality, PCI and Coronary bypass surgery Source funding ACOS is supported by a grant from MSD

angiography or PCI In hospital PCI PCI<48h after admission 44.0 51.8 <0.01 33.2 38.3 <0.01 People who had not had an exercise were significantly less likely to receive ASA, BB, statins pre-discharge than those who had an exercise. Effect Size 1 year follow up No exercise (N=4184) Exercise (N=1097) P value All cause mortality 13.6 5.1 <0.01 PCI 9.1 9.4 0.75 NS Coronary bypass surgery 11.0 7.3 <0.01 Population No exercise Exercise Test P value No in hospital PCI One year mortality 18% 6.9% <0.01 (N=2872) In hospital PCI (N=2409) One year mortality 5.7% 2.2% <0.01 Logistic regression model factors strongly associated with a low rate exercise ing OR (95% CI) Ejection fraction <40% 0.53 (0.42 0.66) Age >70 years 0.54 (0.46 0.62) Prior Stroke / MI 0.61 (0.45 0.83) Diabetes Mellitus 0.78 (0.66 0.91) Sex, reperfusion therapy, beta blocker and statin therapy at discharge were also included in the model.

Ref ID: 4133 Reference Mehta RH, Rao SV, Ohman EM et al. Variation in the use stress ing and outcomes in patients with non-stelevation acute syndromes: insights from GUSTO IIb. Eur Heart J. 2008; 29(7):880-887. Study type/ Evidence level Cohort a GUSTO- 2B RCT comparing hirudin and UFH Level 2+ Number patients N= 8011 13 countries Patient characteristics Intervention Comparison Length followup Patients with NSTE ACS Stress (N=1878) No stress (N=6127) 67 (58-74) P value Age (median, IQR) 63 (54-70) <0.001 Female 26 35 <0.001 Hypertension 43 50 <0.001 Diabetes 14 20 <0.001 Mellitus Current smoker 50 40 <0.001 History 50 60 <0.001 smoking Prior MI 27 33 <0.001 Previous 70 78 <0.001 angina Previous 8 11 <0.001 angioplasty Hyperlipidaemia 41 41 0.688 Family history 38 42 0.013 CAD Previous CABG 12 12 0.401 Stress (23.5%) N=1878 (18% US and 26% non US countries) 70% electrocardiogram alone, 30% other ( echo, sestamibi, radionuclide angiography, thallium) 89% exercise ing, 11% pharmacological provocation Median time from enrolment to stress ing: 6 days No stress (76.5%) N=6127 One year measures Death or non fatal MI (or reinfarction) in the first 30 days follow up, death at 30 days and one year and MI (or reinfarction) at 30 days. Source funding Duke Clinical Research Institute

Angiography No angiography 44 61 <0.001 56 39 Not reported Effect Size HR adjusted for age, gender, race, weight, US vs non-us site, hypertension, diabetes, hypercholesterolemia, history premature CAD, history angina, history PCI, CABG, smoking, CVD,, CHF, lung disease, CRI, PVD, BP at randomisation, HR, rales 6 month data available 7836 (98%) One year data available on 7300 (91%) outcome Stress (N=1878) No stress (N=6127) P value MI (30 days) 3.5 6.8 <0.001 Death (30 days) 0.6 4.8 <0.001 Death or MI (30 days) 3.9 10 <0.001 Death (6 months) 1.8 8.2 <0.001 Death or MI (6 months) 6 15 <0.001 Death, MI or revascularization (6 months) 20 24 <0.001 Death, MI or revascularization (6 months) Kaplan Meier probability and 95% CI 0.19 (0.18 0.20) 0.24 (0.23-0.25) <0.001 Death (1 year) 3.2 11 <0.001 Death (1 year) Kaplan Meier probability and 95% CI 0.03 (0.02-0.04) 0.11 (.11 0.13 <0.001 Compared with no stress ing, stress ing is associated independently with the lower risk : 30-day death (adjusted HR: 0.47, 95% CI 0.24-0.89 p=0.022) 30 day Death or MI (adjusted HR: 0.56, 95% CI 0.38-0.83 p=0.004) 1 year mortality (adjusted HR: 0.58, 95% CI 0.42 0.8 p=0.001) 30 day 1 year mortality (adjusted HR: 0.63, 95% CI 0.45 0.88 p=0.008) Following exclusion pts with cardiac catheterization, MI, recurrent ischaemia, congestive heart failure or death in first 48hrs: 30-day death (adjusted HR: 0.52, 95% CI 0.26-1.05 p=0.067 NS) 30 day Death or MI (adjusted HR: 0.61, 95% CI 0.41-0.90 p=0.014) 1 year mortality (adjusted HR: 0.61, 95% CI 0.43 0.87 p=0.007) 30 day 1 year mortality (adjusted HR: 0.65, 95% CI 0.46 0.93 p=0.017) Composite end point death, MI or revascularization at 6 months was similar in both groups (adjusted HR: 0.99, 95% CI 0.86-1.14 p=0.851 NS) Subgroup Analysis outcome Stress (no angiography) No stress (no angiography) Effect size (95% CI) (calculated by

(N=1061) (N=2404) RF) Death (6 months) 2.0 13.4 OR 0.13 (0.08, 0.21) unadjusted Death or MI (6 months) 4.4 19 OR 0.20 (0.14, 0.27) unadjusted Death, MI or revascularization (6 months) 16 27 OR 0.50 (0.41, 0.60) unadjusted Death (1 year) 3.7 17.4 OR 0.19 (0.13, 0.27) unadjusted